SRSF6调控的可变剪接促进肿瘤进展并为难治性结直肠癌提供治疗靶点
该研究在311例结直肠癌样本及公共数据库中分析SRSF6表达,通过体外和体内实验研究其功能,鉴定其调控的可变剪接及结合基序,并从4855种FDA批准药物中虚拟筛选出SRSF6抑制剂茚达特罗,在体外和体内评估其抗肿瘤效果。
要点
- SRSF6在结直肠癌样本中频繁上调并与不良预后相关。
- SRSF6通过结合ZO-1外显子23基序调控其异常剪接发挥致癌作用。
- 茚达特罗被鉴定为SRSF6抑制剂,可抑制结直肠癌致瘤性。
核心结论
- SRSF6通过调控可变剪接在结直肠癌进展中发挥重要作用。
- 茚达特罗通过靶向SRSF6被重新定位为抗肿瘤药物。
研究设计与样本
- 研究对311例结直肠癌样本、癌症基因组图谱和基因表达综合数据库中的SRSF6表达进行综合分析。
- 在体外和体内进行SRSF6在结直肠癌中的功能分析。
- 通过下一代RNA测序和RNA免疫沉淀测序鉴定SRSF6调控的可变剪接及其结合基序,并经凝胶迁移和微小基因报告分析验证。
- 在体外和体内研究ZO-1外显子23可变剪接介导SRSF6功能。
- 基于结构域特异性作用分析,从4855种FDA批准药物中通过虚拟筛选从头发现SRSF6靶向抑制剂,并在体外和体内评估其抗肿瘤效果。
主要发现
- SRSF6在结直肠癌样本中频繁上调并与不良预后相关,在体外和体内促进增殖和转移。
- 鉴定出SRSF6调控的可变剪接靶点并发现SRSF6结合基序。
- SRSF6通过直接结合ZO-1外显子23中的基序调控其异常剪接,从而发挥致癌基因功能。
- 基于SRSF6 RRM2结构域在调控可变剪接和生物学功能中起关键作用的结果,茚达特罗被鉴定为SRSF6抑制剂,可抑制结直肠癌致瘤性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the molecular function of splicing factor SRSF6 in colorectal cancer (CRC) progression and discover candidate chemicals for cancer therapy through targeting SRSF6. DESIGN: We performed comprehensive analysis for the expression of SRSF6 in 311 CRC samples, The Cancer Genome Atlas and Gene Expression Omnibus (GEO) database. Functional analysis of SRSF6 in CRC was performed in vitro and in vivo. SRSF6-regulated alternative splicing (AS) and its binding motif were identified by next-generation RNA-sequencing and RNA immunoprecipitation sequencing (RIP-seq), which was validated by gel shift and minigene reporter assay. ZO-1 exon23 AS was investigated to mediate the function of SRSF6 in vitro and in vivo. Based on the analysis of domain-specific role, SRSF6-targeted inhibitor was discovered de novoby virtual screening in 4855 FDA-approved drugs and its antitumour effects were evaluated in vitroand in vivo. RESULTS: SRSF6 was frequently upregulated in CRC samples and associated with poor prognosis, which promoted proliferation and metastasis in vitro and in vivo. We identified SRSF6-regulated AS targets and discovered the SRSF6 binding motif. Particularly, SRSF6 regulates ZO-1 aberrant splicing to function as an oncogene by binding directly to its motif in the exon23. Based on the result that SRSF6 RRM2 domain plays key roles in regulating AS and biological function, indacaterol, a β2-adrenergic receptor agonist approved for chronic obstructive pulmonary disease treatment, is identified as the inhibitor of SRSF6 to suppress CRC tumourigenicity. CONCLUSIONS: SRSF6 functions the important roles in mediating CRC progression through regulating AS, and indacaterol is repositioned as an antitumour drug through targeting SRSF6. ACCESSION NUMBERS: The accession numbers for sequencing data are SRP111763 and SRP111797.
引用
- Wan L, Yu W, Shen E, et al. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut. 2017. PMID: 29114070. doi:10.1136/gutjnl-2017-314983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。